Results 41 to 50 of about 2,201,777 (199)

Infographic – INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

, 2022
Infographic – MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib.
Karl Maria Schumacher (11850371), Xiuning Le (11850350), Svenja Adrian (11850365), Viola W Zhu (11850359), Egbert F Smit (9252899), Masahire Morise (11850356), Julien Mazieres (1837), Yi-Long Wu (154004), Figshare Future Science Group (6457551), Daniel Tan (840024), How Soon Hin (11850353), Kristina H Holmberg (11850362), Niki Karachaliou (458283), Jo Raskin (8677218), Ernest Nadal (709876), Sabine Brutlach (11850368), Christophe Dooms (2938749), Barbara Ellers-Lenz (11294394), Lye Mun Tho (8505159)   +18 more
core   +1 more source

EGFR G796D mutation mediates resistance to osimertinib

Oncotarget, 2017
Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of ...
Zheng, Di, Hu, Min, Bai, Yu, Zhu, Xuehua, Lu, Xuesong, Wu, Chunyan, Wang, Jiying, Liu, Li, Wang, Zheng, Ni, Jian, Yang, Zhenfan, Xu, Jianfang   +11 more
openaire   +3 more sources

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer

Thoracic Cancer, 2021
Background The resistance mechanism of the third generation of epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is complex. Epithelial mesenchymal transition (EMT) is a common mechanism of EGFR‐TKI acquired resistance.
Qiong Qin, Xiaoqing Li, Xingmei Liang, Lili Zeng, Jing Wang, Linlin Sun, Diansheng Zhong   +6 more
doaj   +1 more source

Video – INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

, 2022
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib.
Karl Maria Schumacher (11850371), Xiuning Le (11850350), Svenja Adrian (11850365), Viola W Zhu (11850359), Egbert F Smit (9252899), Masahire Morise (11850356), Julien Mazieres (1837), Yi-Long Wu (154004), Figshare Future Science Group (6457551), Daniel Tan (840024), How Soon Hin (11850353), Kristina H Holmberg (11850362), Niki Karachaliou (458283), Jo Raskin (8677218), Ernest Nadal (709876), Sabine Brutlach (11850368), Christophe Dooms (2938749), Barbara Ellers-Lenz (11294394), Lye Mun Tho (8505159)   +18 more
core   +1 more source

Personalized Medicine in Woman Lung Cancer: Crizotinib and Osimertinib Association to Overcome Osimertinib Resistance

Journal of Women's Health and Development, 2020
Non-small cell lung cancer (NSCLC) is the second most diagnosed cancer in women. Research on this type of cancer has benefited from the development of precision medicine for several years. In this case study, elderly women was treated for an advanced NSCLC with brain localization and who has been treated by novel association, osimertinib and crizotinib,
Fanny Leenhardt, Marie Viala, Stephane Pouderoux, Pierre Boisselier, Xavier Quantin   +4 more
openaire   +1 more source

Cezanne promoted autophagy through PIK3C3 stabilization and PIK3C2A transcription in lung adenocarcinoma

Cell Death Discovery, 2023
Osimertinib is a promising approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for treating patients with lung adenocarcinoma (LUAD) harboring EGFR-activating mutations, however, almost all patients develop ...
Yadong Wang, Jiahao Li, Haotian Zheng, Kai Wang, Xiaoyang Ren, Guanghui Wang, Jiajun Du   +6 more
doaj   +1 more source

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports

Frontiers in Pharmacology, 2022
The acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable and heterogeneous. The strategies to overcome acquired resistance are significant.
Yue Zeng, Yuanqing Feng, Guihua Fu, Junlan Jiang, Xiaohan Liu, Yue Pan, Chunhong Hu, Chunhong Hu, Xianling Liu, Fang Wu, Fang Wu, Fang Wu, Fang Wu   +12 more
doaj   +1 more source

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

Thoracic Cancer, 2021
Non‐small cell lung cancer (NSCLC) patients harboring EGFR sensitive mutations may benefit from treatment with EGFR TKIs. Osimertinib, which is an irreversible third‐generation EGFR TKI, has demonstrated a convincing efficacy, irrespective of whether it ...
Helei Hou, Dantong Sun, Chuantao Zhang, Dong Liu, Xiaochun Zhang   +4 more
doaj   +1 more source

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer

Pharmaceutics, 2021
Osimertinib has become a standard of care in the first-line treatment of advanced-stage non-small-cell lung cancer (NSCLC) harboring exon 19 and 21 activating mutations in the EGFR gene.
Frank Aboubakar Nana, Sebahat Ocak
doaj   +1 more source

miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44

Molecular Therapy: Nucleic Acids
Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with EGFR activation or T790M resistance mutations; however, acquired resistance to osimertinib can still develop.
Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Yen-Lin Huang, Chia-Lang Hsu, Han-Nian Jheng, Jin-Yuan Shih   +7 more
doaj   +1 more source